Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION trial of cabozantinib in hepatocellular carcinoma patients intolerant to sorafenib or receiving a non-sorafenib first-line treatment
2019-004991-20Phase 2Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Rate of adverse events with CTCAE grade 3 or higher excluding palmar-plantar erythrodysesthesia. Started Feb 2020; status: terminated.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-004991-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004991-20.